verapamil
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
2229
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
September 24, 2026
Functional assessment of cardiac beat dynamics under dynamic flow: insights from the Mera microphysiological system.
(PubMed, Biomed Microdevices)
- "Pharmacological testing with verapamil, isoproterenol, calcium chloride, and propranolol demonstrated real-time, reversible modulation of beat rate under flow, including recovery following drug-induced suppression. Collectively, these results demonstrate that Mera provides a reproducible, human-relevant platform for modelling cardiomyocyte beat-rate responses to pharmacological modulation under dynamic flow. By enabling dynamic drug exposure and automated analysis, Mera represents a promising approach methodology (NAM) for cardiac drug response testing; incorporation of contractility and electrophysiological readouts will be an important next step toward supporting its use in predictive cardiac safety assessment."
Journal • Cardiovascular
September 19, 2026
Extracts from Eryngium heterophyllum Engelm. [Apiaceae] enhance paclitaxel cytotoxicity in A549 lung cancer cells.
(PubMed, Front Pharmacol)
- "Furthermore, all extracts increased intracellular doxorubicin retention to levels comparable to the reference inhibitor verapamil, suggesting potent inhibition of P-gp mediated efflux. The observed effects may be associated with modulation of drug transport-related mechanisms, including increased intracellular doxorubicin retention and changes in P-gp associated activity. This species represents a promising source of plant-derived metabolites as complementary agents for improving chemotherapy response in lung cancer cells."
Journal • Lung Cancer • Oncology • Solid Tumor
September 06, 2026
Pharmacological basis for the traditional use of Myrica salicifolia root extract in gut motility disorders via cholinergic and calcium/PDE modulation.
(PubMed, J Tradit Complement Med)
- "Further, Ms.Cr caused concentration-dependent (1.0-5.0 mg/mL) relaxation of high K+-induced contractions, similar to papaverine. Preincubated jejunal tissues with Ms.Cr shifted the Ca++ concentration-response curves (CRCs) towards right with suppression of the maximum response, similar to verapamil, thus confirming Ca++ channel blocking activity...sonnei, S. typhimurium and ESβL (extended-spectrum beta-lactamase)-producing E. coli. Thus, this research provides a solid foundation for the therapeutic uses of M. salicifolia in gut motility-related disorders."
Journal
May 30, 2026
Hypoxia-mimicking Conditions Modulate ABC Transporter Expression And Function In Human Aortic Endothelial Cells
(ERS 2026)
- "P-gp and MRP4 inhibitors (verapamil, probenecid) increased rhodamine accumulation (181 ± 40% and 178 ± 15%, p < 0.0001), whereas BCRP inhibitor KO143 had no effect. Hypoxia upregulates P-gp and MRP4 and downregulates ABCA1 in aortic endothelial cells, promoting cholesterol accumulation. This may contribute to metabolic and cardiovascular dysfunction in OSA via altered drug transport, oxidative stress, lipid handling, and vascular integrity. Future studies will expose endothelial cells to plasma from OSA patients before and after CPAP therapy to examine ABC transporter regulation."
Cardiovascular • Inflammation • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • ABCA1 • ABCG1
September 18, 2026
Drugs for prevention of migraine.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • CNS Disorders • Migraine • Pain
September 18, 2026
Unexpected Synergy: Calcium Channel Blockers and Residual Chlorine Cooperatively Accelerate Antibiotic Resistance Dissemination in Water Systems.
(PubMed, Environ Pollut)
- "This study examines the impact of two representative CCBs, amlodipine (AML) and verapamil (VER), on conjugative horizontal gene transfer (HGT) under low-level chlorine conditions...These findings demonstrate that environmental non-antibiotic pharmaceuticals can synergistically promote ARG dissemination under residual chlorine in water supply systems. This study provides a scientific basis for refining risk assessment frameworks for pharmaceutical contaminants in water."
Journal • Acute Myelogenous Leukemia • Gene Therapies
July 06, 2026
REFRACTORY SHOCK FROM INTENTIONAL VERAPAMIL OVERDOSE SUCCESSFULLY TREATED WITH HIGH-DOSE INSULIN THERAPY AND VASOPRESSORS
(CHEST 2026)
- No abstract available
Critical care
September 17, 2026
Utilization of the PK Papyrus Covered Stent for the Treatment of Direct Carotid Cavernous Fistulas: A Case Series.
(PubMed, Neurosurg Pract)
- "The Papyrus covered stent is a viable option in treating direct CCFs. Future multicenter studies are needed to investigate the long-term efficacy of these devices for treatment of CCFs."
Journal • Cardiovascular • Hematological Disorders • Thrombosis
September 16, 2026
ReCAST AF: Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
(clinicaltrials.gov)
- P4 | N=988 | Recruiting | Sponsor: Universitaire Ziekenhuizen KU Leuven | Not yet recruiting ➔ Recruiting
Enrollment open • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease
September 16, 2026
Preventive administration of verapamil attenuates dextran sulfate sodium-induced colitis in mice.
(PubMed, Exp Ther Med)
- "Verapamil also reduced colonic inflammatory cytokine levels, partially reversed DSS-associated alterations in the intestinal microbiota, and preserved the expression of selected tight junction-related proteins and colonic glutathione levels. These findings suggested that verapamil may exert protective effects in this experimental model of colitis; however, further studies are needed to determine its potential clinical relevance in UC."
Journal • Preclinical • Cardiovascular • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
September 14, 2026
Efficacy and Safety of HB-1 for Panic Disorder
(clinicaltrials.gov)
- P2 | N=170 | Terminated | Sponsor: HB BioTech, LLC | Trial completion date: Feb 2027 ➔ Sep 2026 | Suspended ➔ Terminated | Trial primary completion date: Jan 2027 ➔ Sep 2026; Decision to terminate study due to a lack of efficacy in this study population. There were no safety concerns identified that contributed to this decision.
Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Mood Disorders • Psychiatry
September 13, 2026
Construction of a human placental brush border membrane vesicle model for evaluating the effect of antenatal drugs on OCTN1/2 transport function.
(PubMed, Chem Biol Interact)
- "Substrate uptake experiments with ergothioneine and L-carnitine revealed classical saturable concentration-dependent kinetics, which were substantially suppressed by verapamil...However, metformin, glibenclamide, and labetalol moderately inhibited OCTN2, which could hinder placental L-carnitine uptake. Notably, fluoxetine exerted inhibitory effects on both OCTN1 and OCTN2, implying elevated risks of impaired placental antioxidant defense and energy substrate transfer. These findings elucidate the transport characteristics of placental OCTN1/2 and identify unintended inhibitory effects of common antenatal drugs, providing critical experimental references for rational clinical medication during pregnancy."
Journal
September 10, 2026
Repurposing a Dual-Head Programmable Power Injector for Controlled Intra-Arterial Vasodilator Delivery During Cerebral Vasospasm Treatment.
(PubMed, World Neurosurg)
- "One chamber delivers contrast for angiographic runs, while the other contains a triple vasodilator cocktail of verapamil, nicardipine, and nitroglycerin, delivered via the injector's programmable Infusion Mode at operator-defined flow rates and volumes. No procedural complications related to the delivery method occurred. These preliminary findings suggest the dual-head programmable injector provides a feasible, ergonomic, and reproducible closed-system workflow for intra-arterial vasodilator delivery during cerebral vasospasm treatment, with broader applicability to other intra-arterial drug delivery settings."
Journal • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage
September 08, 2026
Edward Miles Vaughan Williams' classification of antiarrhythmic drugs: then and now.
(PubMed, Naunyn Schmiedebergs Arch Pharmacol)
- "The development and approval of novel antiarrhythmic compounds subsequently required more refined subdivision of class I action and a fourth class of action, i.e. 'Ca2+ antagonism' as exemplified by verapamil...The resulting classification was never widely embraced by cardiologists, most likely due to its inherent complexity. Recently, the original Vaughan Williams classification of AAD action has been expanded in order to reflect today's improved knowledge about arrhythmia mechanisms and to include novel targets for AAD actions, but at the same time, the basic concept that proved so useful in the clinical management remained conserved."
Journal • Review • Cardiovascular • Myocardial Infarction
September 07, 2026
Impact of spasmolytic cocktail and Glidesheath Slender on radial artery spasm in transradial cerebral angiography: A randomized factorial trial.
(PubMed, J Vasc Interv Radiol)
- "In this exploratory randomized trial, prophylactic intra-arterial NV did not significantly reduce clinical RAS during diagnostic TRCA. GSS use was associated with higher rates of clinical RAS and RAO under the evaluated procedural conditions. These findings should be interpreted cautiously and require validation in future studies."
Journal
September 05, 2026
Effect of Vitamin D, Verapamil, and Lansoprazole on residual β-cell function in children with newly diagnosed type 1 diabetes: an open-label randomized controlled pilot trial
(ESPE 2026)
- No abstract available
Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
September 05, 2026
Comparative Cardiovascular Outcomes of Verapamil and Carvedilol in MINOCA-Related Coronary Microvascular Dysfunction - A Propensity-Matched Cohort Study
(AHA 2026)
- "Abstract is embargoed at this time."
Cardiovascular
September 05, 2026
Functional characterization of ABC transporters in chlorpyrifos resistance in Nilaparvata lugens.
(PubMed, Pestic Biochem Physiol)
- "Verapamil synergism suggested the involvement of active efflux, and expression profiling identified ABCB7, ABCC5, and ABCG9 as constitutively upregulated in the resistant strain and inducible by chlorpyrifos...Notably, the predicted hydrogen bond was transient, whereas hydrophobic contacts persisted throughout the 100 ns simulation, highlighting the importance of dynamic approaches over static docking alone. These findings identify ABCG9 as a phase III efflux transporter completing the chlorpyrifos detoxification cascade and provide structural insights into substrate recognition by insect ABCG transporters."
Journal • ABCC5
September 05, 2026
Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
(clinicaltrials.gov)
- P2/3 | N=70 | Recruiting | Sponsor: Ain Shams University
New P2/3 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
September 01, 2026
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=84 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD
New P1 trial
August 29, 2026
Multimodal Monitoring in Eclamptic Intracerebral Hemorrhage Complicated by Reversible Cerebral Vasoconstriction Syndrome (RCVS): A Case Report.
(PubMed, Case Rep Crit Care)
- "Treatment with verapamil and levosimendan resulted in rapid normalization of Doppler velocities without systemic hypotension. This case underscores the value of bedside TCCD integrated with multimodal neuromonitoring in the management of a complicated eclampsia with ICH and RCVS. Assessment of cerebral hemodynamics and perfusion may support safe conservative management in high-risk neuro-intensive care patients."
Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Critical care • Epilepsy • Hematological Disorders • Hypertension • Hypotension • Obstetrics
September 04, 2026
Characterization of calcium sources and downstream signaling pathways following electrical field stimulation of rodent longitudinal esophageal muscle.
(PubMed, Front Physiol)
- "Based on our findings with 2-APB, DHBP, and verapamil, extracellular Ca²+ appears to be the source of the increase in intracellular Ca²+ underlying EFS-induced EB contractions. Furthermore, the effects observed with chelerythrine and W-7 may suggest that this increase in intracellular Ca²+ may subsequently activate PKC- and calmodulin-dependent signaling pathways."
Journal • Preclinical
September 03, 2026
Design, synthesis, and biological evaluation of novel phenylindole derivatives as P-gp inhibitors to overcome multidrug resistance in MCF-7/ADR cells.
(PubMed, Bioorg Med Chem)
- "Among these compounds, Ina4 demonstrated potent reversal activity (RF = 229.4), exceeding that of the reference P-gp inhibitors verapamil (RF = 51.0) and cyclosporine A (RF = 103.3), while exhibiting low intrinsic cytotoxicity. Notably, in a 3D tumor spheroid model, co-administration of Ina4 with doxorubicin (DOX) resulted in significant suppression of spheroid growth. Collectively, these findings indicate that Ina4 is a promising P-gp inhibitor."
Journal • Oncology
September 03, 2026
Fengshi Gutong Capsules Alleviate Aconitums-Induced Nephrotoxicity via PXR-Mediated Efflux of Aconitum Alkaloid.
(PubMed, J Ethnopharmacol)
- "FSGT reduces nephrotoxicity via FBXO44/PXR/P-gp signaling to accelerate toxic aconite alkaloids excretion, providing a scientific basis for "detoxification by compatibility" and preclinical mechanistic support for the safety profile of FSGT."
Journal • Immunology • Inflammatory Arthritis • Renal Disease • Rheumatoid Arthritis • Rheumatology • Targeted Protein Degradation • FBXO44
September 03, 2026
Energy-based devices for enhanced transdermal drug delivery in pathological scars: A review.
(PubMed, Lasers Med Sci)
- "These studies evaluated the combined application of various EBDs-including ablative and non-ablative fractional lasers, micro-plasma radiofrequency (MPR), ultrasound, and thermomechanical fractional injury-with pharmacological agents such as corticosteroids, 5-fluorouracil (5-FU), verapamil, botulinum toxin type A (BTXA), and photosensitizers (5-aminolevulinic acid). In summary, EBDs enhance drug delivery through micropore formation or acoustic effects, establishing it as a key therapeutic strategy that balances efficacy with improved safety and patient compliance compared to monotherapy. However, standardized treatment protocols still require further validation through future research."
Journal • Review • Acne Vulgaris • Aesthetic Medicine • Fibrosis • Pain • Pediatrics
1 to 25
Of
2229
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90